Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Psoriasis: Update Bulletin [January 2017]

Product Code:
596200622
Publication Date:
January 2017
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of moderate to severe plaque psoriasis. Topics covered include expert opinions on: UCB and Dermira announcing positive results from its Phase III CIMPASI and CIMPACT programmes, which aims to evaluate the efficacy and safety of Cimzia (certolizumab pegol) in adult patients with moderate-to-severe chronic plaque psoriasis; Sandoz publishing the results from its Phase III EGALITY study in the British Journal of Dermatology, which compared the safety and efficacy of GP2015, a proposed etanercept biosimilar, to Enbrel (etanercept) in patients with moderate-to-severe plaque psoriasis; Janssen Biotech announcing a US and European regulatory submission for guselkumab (formerly CNTO-1959), a human anti-interleukin-23 (IL-23) monoclonal antibody (mAb) being developed as a potential treatment for moderate-to-severe plaque psoriasis.

Business Questions:

  • Does data from the CIMPASI-1 and CIMPASI-2 studies place Cimzia in line with other anti-TNF psoriasis treatments, and what impact does positive data form the CIMPACT study have on KOL perceptions of Cimzia?
  • How influential will insurance coverage, pricing and promotion be in terms of Cimzia’s commercial success as a treatment for psoriasis?
  • At which line of therapy should UCB and Dermira focus on in order to achieve the best commercial outcome for Cimzia in the psoriasis market, and how could this be achieved?
  • Does data from the EGALITY study support GP2015’s role as an etanercept biosimilar, or do KOLs still have any lingering concerns?
  • Following its approval in the US, what market access issues are likely to be most influential in dictating Erelzi’s positioning in the US?
  • In Europe, will the EGALITY data have any impact on the uptake of Benepali?
  • What lingering concerns are preventing KOLs from making any firm predictions about the future of guselkumab; is it safety, efficacy or something else?
  • Do KOLs predict clinical superiority of guselkumab versus Humira and Stelara from the VOYAGE 2 and NAVIGATE studies, or is something else likely to happen?
  • How much influence will regulatory and economic decisions have on guselkumab’s potential as a first-line therapy for psoriasis, and does this have any impact on guselkumab’s gold-standard prospects?

 




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved